8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) April 7, 2010

Bio-Reference Laboratories, Inc.

(Exact name of registrant as specified in its charter)

New Jersey	0-15266	22-2405059
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)

481 Edward H. Ross Drive, Elmwood Park, NJ 07407

(Address of principal executive offices) (Zip Code)

(201) 791-2600

Registrant’s telephone number, including area code

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01Other Events

On Wednesday, April 7, 2010, the Registrant announced a two for one split of its Common Stock, payable to stockholders of record at the close of business on Monday, April 19, 2010. Pursuant to the stock split, each stockholder will receive one additional share of the Registrant’s Common Stock for each share of the Registrant’s Common Stock owned on the record date. Copies of the Notice provided to NASDAQ pursuant to Rule 10b-17 of the Securities Exchange Act and of the Press Release announcing the stock split are enclosed.

Item 9.01Financial Statements and Exhibits

(d) Exhibits — 99.1 Notice of the two for one Common Stock Split filed pursuant to Securities Exchange Act Rule 10b-17

99.2 Press Release dated April 7, 2010 announcing the two for one stock split

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed in its behalf by the undersigned hereunto duly authorized.

		Bio-Reference Laboratories, Inc.
		(Registrant)
		By	/s/ Marc D. Grodman
			Marc D. Grodman, President
Date:	April 8, 2010

2

EX-99.1

Exhibit 99.1

NOTICE OF TWO FOR ONE COMMON STOCK SPLIT

NASDAQ Corporate Data Dep’t	April 7, 2010
2 Corporate Drive – 300
Shelton, CT 06484
	Re: Bio-Reference Laboratories (“BRLI”)

Ladies and Gentlemen,

Pursuant to Securities Exchange Act Rule 10b-17, notice is hereby given that BRLI’s board of directors has approved and declared a two for one stock split of its Common Stock. Pursuant to the stock split, each BRLI stockholder will receive one additional share of BRLI Common Stock for each share of BRLI Common Stock owned on the record date. The details are as follows:

(i)Title of the security — Common Stock, $.01 par value

(ii)Date of declaration — April 7, 2010

(iii)Record Date for determining holders of record entitled to participate in the stock split — Close of business on April 19, 2010

(iv)Anticipated date of delivery (mailing date) of the distribution — April 21, 2010

(v)(b)The number of shares of Common Stock outstanding;

(1) immediately prior to the distribution of the two for one stock split. 13,880,986 shares

(2) immediately following the distribution of the two for one stock split. 27,761,972 shares.

(viii)The name and address of BRLI’s transfer agent is as follows:

American Stock Transfer and Trust Company

6201 15th Avenue

Brooklyn, New York 11219

	Very truly yours,
	Bio-Reference Laboratories, Inc.
By	/S/ Sam Singer
	Sam Singer
	Senior Vice President and
	Chief Financial Officer

EX-99.2

Exhibit 99.2

FOR:	BIOREFERENCE LABORATORIES, INC.
CONTACT:	Tara Mackay, Investor Relations
	(201) 791-2600
	(201) 791-1941 (fax)
	tmackay@bioreference.com

BIOREFERENCE LABORATORIES, INC. ANNOUNCES 2 FOR 1 STOCK SPLIT

- - -

Company will execute stock split on April 19, 2010

ELMWOOD PARK, NJ (Wednesday, April 7, 2010)- BioReference Laboratories, Inc. (NASDAQ: BRLI) announced the approval by its board of directors and the declaration today of a forward two for one split of its Common Stock entitling each holder of record of BRLI Common Stock at the close of business on April 19, 2010 to receive one additional share of BRLI Common Stock for each share owned by him or her at such time. Distribution of the additional shares is expected to be made on or about April 21, 2010.

Marc Grodman, MD, CEO, stated “The announced stock split will meaningfully increase our outstanding shares and is consistent with our overall capital management strategy and our commitment to driving sustainable shareholder value.”

About BioReference Laboratories, Inc.

BRLI is the third largest full service laboratory in the United States and the largest independent regional laboratory in the Northeastern market, primarily a clinical testing lab servicing physician offices with concentrations in the focused markets of esoteric testing, molecular diagnostics, anatomical pathology and correctional health care.  BRLI operates as a national oncology laboratory under its GenPath label.  Better science, superior technology and better service have enabled GenPath to earn a reputation as one of the premier hematopathology laboratories in the country.  BRLI’s innovative technology platform for sexually transmitted infections has enabled it to expand as a national laboratory in the area of Women’s Health.   GeneDx, a wholly owned subsidiary, is the BRLI genetics laboratory and is typically recognized as the leading laboratory for testing of rare genetic diseases; GeneDx has now become a technology leader with GenomeDx, based on a CGH array platform and its NextGen sequence offerings that are currently offered in cardiology and will be offered in the future in other disease specific areas.

# # #

Statements included in this release that are not historical in nature, are intended to be, and are hereby identified as “forward-looking statements”. Statements looking forward in time are included in this release pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks and uncertainties that may cause the Company’s actual results in future periods to be materially different from any future performance suggested herein.